NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Symbol: NASDAQ:NURO
- CUSIP: N/A
- Web: www.neurometrix.com
Capitalization:- Market Cap: $4.25 million
- Outstanding Shares: 2,126,000
Average Prices:- 50 Day Moving Avg: $1.97
- 200 Day Moving Avg: $1.88
- 52 Week Range: $0.38 - $4.50
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.23
- P/E Growth: -0.01
Sales & Book Value:- Annual Revenue: $15.72 million
- Price / Sales: 0.27
- Book Value: $2.83 per share
- Price / Book: 0.71
Profitability:- EBIDTA: ($13,270,000.00)
- Net Margins: -83.92%
- Return on Equity: -209.56%
- Return on Assets: -135.03%
Debt:- Current Ratio: 2.13%
- Quick Ratio: 1.73%
Misc:- Average Volume: 46,827 shs.
- Beta: 0.38
- Short Ratio: 1.7
Frequently Asked Questions for NeuroMetrix (NASDAQ:NURO)
What is NeuroMetrix's stock symbol?
NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."
When did NeuroMetrix's stock split? How did NeuroMetrix's stock split work?
NeuroMetrix shares reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of NeuroMetrix stock prior to the reverse split would have 13 shares after the split.
How were NeuroMetrix's earnings last quarter?
NeuroMetrix, Inc. (NASDAQ:NURO) issued its earnings results on Thursday, July, 20th. The company reported ($2.49) earnings per share for the quarter, beating the consensus estimate of ($2.83) by $0.34. The company earned $4.31 million during the quarter, compared to analysts' expectations of $4.40 million. NeuroMetrix had a negative net margin of 83.92% and a negative return on equity of 209.56%. View NeuroMetrix's Earnings History.
When will NeuroMetrix make its next earnings announcement?
Where is NeuroMetrix's stock going? Where will NeuroMetrix's stock price be in 2017?
2 analysts have issued 12-month price objectives for NeuroMetrix's shares. Their forecasts range from $16.00 to $36.00. On average, they anticipate NeuroMetrix's stock price to reach $26.00 in the next twelve months. View Analyst Ratings for NeuroMetrix.
Who are some of NeuroMetrix's key competitors?
Some companies that are related to NeuroMetrix include Opexa Therapeutics (OPXA), ESSA Pharma (EPIX), Ritter Pharmaceuticals (RTTR), TearLab Corporation (TEAR), Kitov Pharmaceuticals Holdings (KTOV), Senesco Technologies (SVON), OncoGenex Pharmaceuticals (ACHV), Avinger (AVGR), Rosetta Genomics (ROSG), Roka Bioscience (ROKA), Strata Skin Sciences (SSKN), Windtree Therapeutics (WINT), Affymax (AFFY), Adeptus Health (ADPT), Bayer AG (BAYRY), DNIB Unwind (BIND), Echo Therapeutics (ECTE) and Epirus Biopharmaceuticals (EPRS).
Who are NeuroMetrix's key executives?
NeuroMetrix's management team includes the folowing people:
- Shai N. Gozani M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer, Secretary
- Thomas T. Higgins, Chief Financial Officer, Senior Vice President, Treasurer
- Francis X. McGillin, Senior Vice President, General Manager - Consumer Wearables
- David E. Goodman M.D., Independent Director
- Allen J. Hinkle M.D., Independent Director
- Nancy E. Katz, Independent Director
- Timothy R. Surgenor, Independent Director
- David Van Avermaete, Independent Director
How do I buy NeuroMetrix stock?
Shares of NeuroMetrix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeuroMetrix's stock price today?
One share of NeuroMetrix stock can currently be purchased for approximately $2.00.
MarketBeat Community Rating for NeuroMetrix (NASDAQ NURO)MarketBeat's community ratings are surveys of what our community members think about NeuroMetrix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for NeuroMetrix (NASDAQ:NURO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $26.00 (1,200.00% upside) |
Analysts' Ratings History for NeuroMetrix (NASDAQ:NURO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/15/2017 | HC Wainwright | Set Price Target | Buy | $16.00 | Low |  |
| 10/21/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $36.00 | N/A | |
| 2/29/2016 | Dawson James | Reiterated Rating | Buy | | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for NeuroMetrix (NASDAQ:NURO)Earnings History by Quarter for NeuroMetrix (NASDAQ NURO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/18/2017 | | | | | | | N/A | |
| 7/20/2017 | Q2 2017 | ($2.83) | ($2.49) | $4.40 million | $4.31 million | View | N/A | |
| 4/20/2017 | Q1 2017 | ($3.92) | ($7.28) | $4.17 million | $4.31 million | View | N/A | |
| 1/26/2017 | Q416 | ($6.00) | ($4.16) | $3.48 million | $3.70 million | View | Listen | |
| 10/20/2016 | Q316 | ($6.56) | ($6.08) | $3.01 million | $3.39 million | View | Listen | |
| 7/21/2016 | Q216 | ($7.44) | ($42.96) | $1.22 million | $2.65 million | View | Listen | |
| 4/21/2016 | Q116 | ($7.60) | ($8.00) | $2.65 million | $2.28 million | View | Listen | |
| 10/22/2015 | Q315 | ($0.64) | ($2.08) | $6.47 million | $2.10 million | View | Listen | |
| 7/22/2015 | Q215 | | ($3.84) | $9.80 million | $1.22 million | View | Listen | |
| 2/12/2015 | Q414 | | ($2.88) | $4.62 million | $1.41 million | View | N/A | |
| 7/24/2014 | Q413 | | ($6.80) | $1.16 million | $1.34 million | View | N/A | |
| 2/13/2014 | | | ($6.96) | | | View | Listen | |
| 10/23/2013 | Q313 | | ($2.08) | $1.77 million | $1.31 million | View | Listen | |
| 7/25/2013 | Q2 2013 | | ($7.36) | $2.20 million | $1.20 million | View | N/A | |
| 2/3/2011 | | ($1.36) | ($1.44) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for NeuroMetrix (NASDAQ:NURO)Current Year EPS Consensus Estimate: $-11.2 EPS
Next Year EPS Consensus Estimate: $-1.62 EPS
Dividend History for NeuroMetrix (NASDAQ:NURO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NeuroMetrix (NASDAQ:NURO)Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 6.53%
Insider Trades by Quarter for NeuroMetrix (NASDAQ:NURO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/21/2017 | Thomas T Higgins | Insider | Buy | 1,000 | $2.83 | $2,830.00 | |
| 6/16/2017 | Shai Gozani | CEO | Buy | 3,500 | $2.90 | $10,150.00 | |
| 6/15/2017 | Thomas T Higgins | Insider | Buy | 3,500 | $2.98 | $10,430.00 | |
| 6/14/2017 | Shai Gozani | CEO | Buy | 5,000 | $2.97 | $14,850.00 | |
| 6/14/2017 | Thomas T Higgins | Insider | Buy | 2,300 | $2.97 | $6,831.00 | |
| 11/1/2016 | Shai Gozani | CEO | Buy | 3,000 | $1.31 | $3,930.00 | |
| 10/28/2016 | Thomas T Higgins | Insider | Buy | 3,000 | $1.32 | $3,960.00 | |
| 10/27/2016 | Shai Gozani | CEO | Buy | 6,000 | $1.32 | $7,920.00 | |
| 8/31/2016 | Thomas T Higgins | CFO | Buy | 1,400 | $1.41 | $1,974.00 | |
| 8/18/2016 | Shai Gozani | CEO | Buy | 5,000 | $1.49 | $7,450.00 | |
| 8/12/2016 | Thomas T Higgins | Insider | Buy | 2,000 | $1.45 | $2,900.00 | |
| 6/1/2016 | Shai Gozani | CEO | Buy | 2,500 | $1.71 | $4,275.00 | |
| 5/23/2016 | Francis X Mcgillin | VP | Buy | 1,000 | $1.65 | $1,650.00 | |
| 5/19/2016 | Shai Gozani | CEO | Buy | 12,000 | $1.55 | $18,600.00 | |
| 5/19/2016 | Thomas T Higgins | CFO | Buy | 3,200 | $1.54 | $4,928.00 | |
| 8/28/2015 | Thomas T Higgins | CFO | Buy | 4,500 | $0.92 | $4,140.00 | |
| 8/20/2015 | Thomas T Higgins | CFO | Buy | 5,500 | $0.91 | $5,005.00 | |
| 8/11/2015 | Shai Gozani | CEO | Buy | 16,300 | $0.91 | $14,833.00 | |
| 11/9/2012 | Shai Gozani | CEO | Buy | 26,800 | $0.55 | $14,740.00 | |
| 8/27/2012 | Krishnamurthy Balachandran | COO | Buy | 5,000 | $0.67 | $3,350.00 | |
| 8/21/2012 | Thomas T Higgins | CFO | Buy | 5,000 | $0.64 | $3,200.00 | |
| 8/13/2012 | Krishnamurthy Balachandran | COO | Buy | 5,000 | $0.70 | $3,500.00 | |
| 8/8/2012 | Thomas T Higgins | CFO | Buy | 5,000 | $0.70 | $3,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for NeuroMetrix (NASDAQ:NURO)
Latest Headlines for NeuroMetrix (NASDAQ:NURO)
| Source: |
|
| Date | Headline |
|---|
 | Head to Head Contrast: Tandem Diabetes Care (TNDM) versus NeuroMetrix (NURO)
www.americanbankingnews.com - September 19 at 12:56 PM |
 | Before You Buy NeuroMetrix Inc’s (NURO), You Should Consider This
finance.yahoo.com - September 19 at 5:44 AM |
 | NeuroMetrix (NURO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 7:16 AM |
| Comparing Asante Solutions (PUMP) & NeuroMetrix (NURO)
www.americanbankingnews.com - September 9 at 6:44 PM |
| Syneron Medical (ELOS) vs. NeuroMetrix (NURO) Financial Analysis
www.americanbankingnews.com - September 8 at 10:28 PM |
| NeuroMetrix Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12th, 2017
finance.yahoo.com - September 6 at 7:02 AM |
| Two Studies Derived from Quell Health Cloud to be Presented at Upcoming PAINWeek National Conference
finance.yahoo.com - September 1 at 6:31 AM |
| NeuroMetrix Teams Up with U.S. Pain Foundation to Raise Awareness of Chronic Pain
finance.yahoo.com - August 30 at 7:25 AM |
| Comparing Asante Solutions (PUMP) and NeuroMetrix (NURO)
www.americanbankingnews.com - August 17 at 4:50 AM |
| NeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep
finance.yahoo.com - August 15 at 4:32 PM |
| NeuroMetrix Announces DPNCheck Distribution Agreement with Fukuda Denshi in Japan
finance.yahoo.com - August 4 at 6:27 AM |
 | NeuroMetrix Announces Shipment of 100000 - Business Wire (press release)
www.businesswire.com - July 29 at 5:41 AM |
| NeuroMetrix Announces Shipment of 100,000th Quell Device Since Launch in 2015
finance.yahoo.com - July 28 at 6:18 AM |
| NeuroMetrix, Inc. :NURO-US: Earnings Analysis: Q2, 2017 By the Numbers : July 24, 2017
finance.yahoo.com - July 25 at 6:19 AM |
| NeuroMetrix Reports Q2 2017 Financial Results - Business Wire (press release)
www.businesswire.com - July 22 at 7:05 AM |
| NeuroMetrix, Inc. (NURO) Announces Earnings Results
www.americanbankingnews.com - July 21 at 11:05 AM |
| Investor Network: NeuroMetrix, Inc. to Host Earnings Call
finance.yahoo.com - July 21 at 4:30 AM |
| NeuroMetrix Reports Q2 2017 Financial Results
finance.yahoo.com - July 21 at 4:30 AM |
| Edited Transcript of NURO earnings conference call or presentation 20-Jul-17 12:00pm GMT
finance.yahoo.com - July 21 at 4:30 AM |
| NeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call - Business Wire (press release)
www.businesswire.com - July 13 at 7:27 AM |
| NeuroMetrix, Inc. Announces Date for 2017 Second Quarter Financial Results Conference Call
finance.yahoo.com - July 13 at 7:27 AM |
| NeuroMetrix, Inc. (NURO)
seekingalpha.com - July 12 at 6:30 AM |
| NeuroMetrix Announces $7.0 Million Private Placement of Preferred Stock
finance.yahoo.com - July 11 at 6:04 AM |
| NeuroMetrix Reports Promotion of Michael MacDonald to Senior Vice President and General Manager of Diagnostics
finance.yahoo.com - July 6 at 7:35 AM |
| Zacks Investment Research Upgrades NeuroMetrix, Inc. (NASDAQ:NURO) to Buy
www.americanbankingnews.com - July 5 at 7:32 AM |
| NeuroMetrix Provides Update on Quell Health Cloud Including ... - Business Wire (press release)
www.businesswire.com - June 27 at 6:49 AM |
| NeuroMetrix Provides Update on Quell Health Cloud Including Promotion of Dr. Xuan Kong to Chief Data Scientist
finance.yahoo.com - June 27 at 6:49 AM |
| NeuroMetrix Provides Update on Quell Wearable Pain Relief Clinical Program
finance.yahoo.com - June 23 at 7:30 PM |
| Insider Buying: NeuroMetrix, Inc. (NURO) CEO Acquires 3,500 Shares of Stock
www.americanbankingnews.com - June 16 at 4:50 PM |
| HC Wainwright Analysts Give NeuroMetrix, Inc. (NURO) a $16.00 Price Target
www.americanbankingnews.com - June 16 at 1:16 AM |
| Insider Buying: NeuroMetrix, Inc. (NURO) Insider Acquires 3,500 Shares of Stock
www.americanbankingnews.com - June 15 at 8:08 PM |
| NeuroMetrix, Inc. (NURO) CEO Acquires $14,850.00 in Stock
www.americanbankingnews.com - June 14 at 4:28 PM |
| Today's Research Reports on Stocks to Watch: Cleantech Solutions and NeuroMetrix
finance.yahoo.com - June 14 at 9:14 AM |
| NeuroMetrix (NURO) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 9 at 7:07 PM |
| NeuroMetrix to Present at the Marcum Microcap Conference on June 16, 2017
finance.yahoo.com - June 8 at 9:45 AM |
| NeuroMetrix Exhibits Quell Wearable Technology at 31st Annual SLEEP Meeting
finance.yahoo.com - June 6 at 7:39 PM |
| Neurometrix Inc (NURO) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - June 3 at 11:58 PM |
| NeuroMetrix to Present at the LD Micro Invitational Conference on June 6, 2017
finance.yahoo.com - May 30 at 9:04 AM |
| NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable Pain Relief Technology
finance.yahoo.com - May 22 at 6:10 PM |
| Neurometrix Inc (NURO) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 2:50 PM |
| NeuroMetrix Wins SBANE New England Innovation Award
finance.yahoo.com - May 17 at 6:52 PM |
 | NeuroMetrix (NURO) Says Preliminary Results from Study Evaluating Quell in Chemotherapy-Induced Peripheral Neuropathy to be Presented at APS Meeting
www.streetinsider.com - May 16 at 10:10 AM |
| NeuroMetrix Launches the LivingQuell Blog, a New Platform for Exploring Perspectives on Chronic Pain
finance.yahoo.com - May 16 at 10:10 AM |
| Preliminary Results from Clinical Study Evaluating Use of Quell in Chemotherapy-Induced Peripheral Neuropathy to be presented at the American Pain Society Annual Meeting
finance.yahoo.com - May 15 at 6:14 PM |
| NeuroMetrix (NURO) Declares 1-for-8 Reverse Stock Split
www.streetinsider.com - May 13 at 8:20 AM |
| NeuroMetrix Announces One-for-Eight Reverse Split
finance.yahoo.com - May 11 at 7:24 PM |
| NeuroMetrix (NURO) Announces Expansion of International Intellectual Property Assets for Quell
www.streetinsider.com - May 8 at 6:24 PM |
| NeuroMetrix Reports Substantial Expansion of International Intellectual Property Assets for Quell Wearable Pain Relief Technology
www.businesswire.com - May 8 at 12:15 PM |
| NeuroMetrix Hosts Inaugural Quell User Event
finance.yahoo.com - May 5 at 7:11 PM |
| Neurometrix (NURO) Getting Somewhat Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 3:24 PM |
NeuroMetrix (NURO) Chart for Friday, September, 22, 2017
